 AIM ImmunoTech Inc. said it has submitted a pre-Investigational New Drug Pre-IND application to the US Food and Drug Administration FDA for a Phase 2 clinical study of Ampligen as a potential infusion therapy for post-coronavirus COVID-19 Cognitive Dysfunction PCCD. 